Key result
RSV hospitalizations are complicated by acute cardiovascular events in up to ~22% of adults.
Why the study?
The impact of respiratory syncytial virus on cardiovascular disease in older adults and associated health care utilization and outcomes is increasingly recognized but not fully characterized.
Adults with underlying cardiovascular disease are at high risk for RSV-related hospitalization and complications, representing an important target population for RSV vaccination.
Respiratory syncytial virus (RSV) is historically known for causing respiratory illness in young children, but the appreciation of its impact on older adults is growing. Studies have shown that hospitalization for respiratory illness due to RSV is complicated by cardiovascular events in 14% to 22% of adult patients, including worsening congestive heart failure, acute coronary syndrome, and arrhythmias. Additionally, underlying cardiovascular disease is associated with hospitalization in 45% to 63% of adults with confirmed RSV. In summary, patients with cardiopulmonary disease have higher rates of health care utilization for RSV-related illness and worse outcomes. Patients with cardiovascular disease likely represent an important target population for the rapidly developing field of RSV vaccines.
No takes yet. Share an insight, caveat, or question.
Ivey et al. (2018) conducted a review in Respiratory Syncytial Virus and Cardiovascular Disease. Respiratory Syncytial Virus (RSV) was evaluated. Respiratory syncytial virus hospitalization is complicated by cardiovascular events in 14-22% of adults, and underlying cardiovascular disease is present in 45-63% of adults hospitalized with RSV.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: